Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Chimeric Therapeutics Ltd. has announced the issuance of 197,203,052 securities under an Entitlement Offer, as per the prospectus dated March 18, 2025. This move is part of the company’s strategy to enhance its financial position and support its ongoing research and development efforts in the field of cancer therapeutics.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is dedicated to advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies, aiming to address unmet medical needs in oncology.
Technical Sentiment Signal: Buy
Current Market Cap: A$11.34M
See more data about CHM stock on TipRanks’ Stock Analysis page.